Effective Drug Delivery System for Duchenne Muscular Dystrophy Using Hybrid Liposomes Including Gentamicin along with Reduced Toxicity

• Yukihara Mamiko

  Division of Applied Life Science, Graduate School of Engineering, Sojo University

• Ito Kaori

  Department of Child Development, Graduate School of Medical Sciences, Kumamoto University

• Tanoue Osamu

  Division of Applied Life Science, Graduate School of Engineering, Sojo University

• Goto Koichi

  Division of Applied Life Science, Graduate School of Engineering, Sojo University

• Matsushita Taku

  Division of Applied Life Science, Graduate School of Engineering, Sojo University

• Matsumoto Yoko

  Division of Applied Life Science, Graduate School of Engineering, Sojo University

• Masuda Masako

  Department of Otolaryngology, Graduate School of Medical Sciences, Kumamoto University

• Kimura Shigemi

  Department of Child Development, Graduate School of Medical Sciences, Kumamoto University

• Ueoka Ryuichi

  Division of Applied Life Science, Graduate School of Engineering, Sojo University

抄録

It is known that gentamicin (GM) could be a possible treatment for Duchenne Muscular Dystrophy (DMD). However, GM therapy has been hindered by several problems such as severe side effects of GM. In order to resolve these problems, we developed the drug delivery system (DDS) of GM using hybrid liposomes (HL) composed of L-α-dimyristoylphosphatidylcholine (DMPC) and polyoxyethylene(23) lauryl ether (C₁₂(EO)₂₃). The hydrodynamic diameters of HL including GM (GM-HL) were 60—90 nm with a narrow range of the size distribution and the sizes were kept almost constant for over 4 weeks, suggesting that GM-HL could avoid the reticuloendothelial system in vivo. Furthermore, GM-HL accumulated more to the skeletal muscle cells of X chromosome-linked muscular distrophy (mdx) mice as compared to those of normal mice. Significantly, we succeeded in increasing dystrophin positive fibers in skeletal muscle cells of mdx mice using GM-HL along with the reduction of ototoxicity. It is suggested that GM should be carried more efficiently into the muscular cells of mdx mice by HL. These results indicate that HL could be an effective carrier in the DDS of GM therapy for DMD.

収録刊行物

• Ｂｉｏｌｏｇｉｃａｌ　＆　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｂｕｌｌｅｔｉｎ

  Ｂｉｏｌｏｇｉｃａｌ　＆　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｂｕｌｌｅｔｉｎ 34 (5), 712-716, 2011

  公益社団法人 日本薬学会

キーワード

• Duchenne muscular dystrophy
• hybrid liposome
• gentamicin
• drug delivery system
• X chromosome-linked muscular distrophy mouse

詳細情報

• CRID: 1390282679601900288
• NII論文ID: 130000657785
• NII書誌ID: AA10885497
• DOI: 10.1248/bpb.34.712
• COI: 1:STN:280:DC%2BC3MvnsFajug%3D%3D
• ISSN: 13475215
• ISSN: 09186158
• NDL書誌ID: 11057949
• PubMed: 21532162
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I11057949
• Web Site: http://www.jstage.jst.go.jp/article/bpb/34/5/34_5_712/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2012069549
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• 抄録ライセンスフラグ: 使用不可